Transgene (TNG.PA)

Executive Summary

Transgene SA is a French biotechnology company developing immunotherapies for cancer using viral vector platforms, including engineered vaccinia viruses and adenoviruses. Its lead platforms, Invir.IO™ (oncolytic viruses) and myvac™ (cancer vaccines), aim to stimulate patients' immune systems to target and destroy tumor cells. The company's pipeline focuses on solid tumors such as head and neck, lung, and ovarian cancers, with several candidates in early-to-mid-stage clinical trials. Transgene leverages strategic collaborations with academic and industry partners to advance its programs and has a history of public funding through Euronext Paris. In the near term, Transgene is expected to report key clinical data readouts from its ongoing trials, particularly for its myvac™ personalized vaccine platform and Invir.IO™ oncolytic virus candidates. The company's ability to demonstrate efficacy and safety in these studies will be critical for valuation and potential partnership opportunities. Additionally, progress in manufacturing scale-up and regulatory interactions could serve as near-term catalysts. While Transgene's platform technology holds promise in the immuno-oncology space, its success hinges on positive clinical outcomes and competitive differentiation in a crowded field.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 data readout for TG4050 (myvac™) in head and neck cancer55% success
• Q4 2026Initiation of Phase 2 trial for BT-001 (Invir.IO™) in ovarian cancer70% success
• TBDNew strategic partnership for Invir.IO™ platform40% success